Understanding how collagen is processed in lung fibrosis
Official title: Intracellular Collagen Sensing in Pulmonary Fibrosis
Funded at Weill Medical Coll of Cornell Univ · NIH-10980079 · Data updated 2026-11-12
This study is looking into how the lungs build up collagen in people with Idiopathic Pulmonary Fibrosis (IPF), which makes it hard to breathe, and aims to find new ways to help clear that collagen to improve treatment options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 15, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $595,286 |
| NIH project number | 1R01HL169611-01A1 |
| Project ID | NIH-10980079 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Idiopathic Pulmonary Fibrosis who are experiencing symptoms such as breathlessness.
✕Less likely to help
Patients with other forms of lung disease or those without a diagnosis of Idiopathic Pulmonary Fibrosis may not benefit from this research.
What this research studies
This research investigates the mechanisms behind collagen accumulation in Idiopathic Pulmonary Fibrosis (IPF), a condition that leads to severe breathing difficulties and lung damage. By using advanced CRISPR screening techniques, the study aims to identify how cells sense and regulate collagen levels, which could help in developing new therapies to promote collagen clearance in patients with IPF. The research focuses on a specific protein that plays a crucial role in this process, potentially leading to breakthroughs in treatment options for affected individuals.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that reverse lung fibrosis and improve breathing in patients with IPF.
How similar studies have gone: Other research has shown promise in understanding collagen dynamics in fibrosis, but this specific approach using CRISPR technology is relatively novel.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Podolsky, Michael — Weill Medical Coll of Cornell Univ
- Study coordinator: Podolsky, Michael
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
-
Alveolar Cell Dysfunction in Pulmonary Fibrosis: Using SFTPC Mutations to Find New Targets
This grant explores how rare SFTPC mutations in alveolar cells may drive IPF and seeks new molecular targets to improve treatment.
-
Iron and scar-forming cells in the lungs (IPF)
Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Role of lactate transporters in lung scarring
Aims to see if blocking lactate transporters can slow or stop scar-forming cells from thickening the lungs in people with fibrotic lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.